Responding to a Broad Agency Announcement (BAA-NIAID-DMID-NIHAI2012149) solicitation titled “Development of Therapeutic Medical Countermeasures for Biodefense and Emerging Infectious Diseases”, Venatorx Pharmaceuticals was selected to execute a research and development contract around proprietary compounds that address resistant NIAID Category A, B, and C pathogens. The contract award is for up to $21.2M. READ FULL TEXT
Author: @admin
VenatoRx Awarded Phase II SBIR Grant
VenatoRx was awarded a Phase 2 SBIR Grant for novel approaches to address multi-drug resistant gram-negative infections. VenatoRx may receive up to $3M of funding under the grant. READ FULL TEXT
Venatorx Pharmaceuticals Awarded Phase II SBIR Grant
Venatorx Pharmaceuticals was awarded a Phase 2 SBIR Grant for novel approaches to address multi-drug resistant gram-negative infections. Venatorx may receive up to $3M of funding under the grant. READ FULL TEXT
Vincent Milano Joins VenatoRx Board of Directors
Mr. Milano is the President, Chief Executive Officer, and Chairman of the Board of Directors of ViroPharma. READ FULL TEXT
Vincent Milano Joins Venatorx Pharmaceuticals Board of Directors
Mr. Milano is the President, Chief Executive Officer, and Chairman of the Board of Directors of ViroPharma. READ FULL TEXT
Ezra Felker Joins VenatoRx as Chief Business Officer
Mr. Felker brings over 20 years of experience in biotechnology, pharmaceutical, and diagnostics, spanning business development, operations, and venture capital. READ FULL TEXT
Ezra Felker Joins Venatorx Pharmaceuticals as Chief Business Officer
Ezra Felker has joined Venatorx Pharmaceuticals as Chief Business Officer. Mr. Felker brings over 20 years of experience in biotechnology, pharmaceutical, and diagnostics, spanning business development, operations, and venture capital. Read Ezra Felker’s bio. READ FULL TEXT
VenatoRx Awarded Phase I SBIR Grant
VenatoRx has been awarded a Phase 1 SBIR Grant for novel approaches to address multi-drug resistant gram-negative infections. The company may receive up to $600,000 of funding under the grant. READ FULL TEXT
VenatoRx Awarded Phase I SBIR Grant
VenatoRx has been awarded a Phase 1 SBIR Grant for novel approaches to address multi-drug resistant gram-negative infections. The company may receive up to $600,000 of funding under the grant. READ FULL TEXT
VenatoRx Awarded Phase I SBIR Grant
VenatoRx has been awarded a Phase 1 SBIR Grant for novel approaches to address multi-drug resistant gram-negative infections. The company may receive up to $600,000 of funding under the grant. READ FULL TEXT